Sandoz Egypt plans to launch new medicines targeting 12 million patients


El Bagoury: Sandoz is expanding its market share… and the local market is developing

The Ministry of Health has made a great effort in registering and making the “Corona” vaccine available in record time

Sandoz Egypt Pharmaceuticals plans to launch several new medicines in the last quarter of this year, while it aims to provide medicines to about 12 million patients at competitive prices and international quality during 2022.

Sameh El-Bagoury, Chairman of the Board of Directors of Sandoz Egypt Pharmaceutical Company, said that the company is growing significantly, and is witnessing a continuous expansion in its market share, and this requires pumping new investments in producing factories.

Al-Bagoury added in an interview with “Al Borsa” that the company’s investments are not limited to adding production capacities only, but the company provides new job opportunities constantly, pointing out that the company expanded this year by increasing its human capacity by about 15%, and the company will continue its investments during 2022.

He added that Sandoz plans to offer two medicines for patients with rheumatoid arthritis and psoriasis and a medicine for breast cancer patients during the current quarter of 2021, as this type is the largest type of cancer in the world and in Egypt.

The company aims to reach a larger number of rheumatic patients, by offering a drug that is used as a long-acting analgesic with strong effectiveness and less damage to the digestive system.

The plan to launch new medicines for 2022 also includes two antibiotics intended for hospital use, which work to cover a wider range of bacteria effectively and safely.

He pointed out that “Sandoz Egypt” provides the patient with several preparations from the category of nutritional supplements, which are used medically as an auxiliary factor with medicines to relieve symptoms of the disease, and it is expected that the company will launch during the coming period a product that stimulates immunity and helps regulate the movement of the digestive system.

Sandoz is one of Novartis’s segments, and it owns a large product portfolio of about 1,000 types in various therapeutic areas, which puts it in a leading position in the field of analogues and biosimilars.

Sandoz includes a diversified portfolio in Egypt that includes treatments for many different diseases, such as anti-infectives, respiratory diseases, pain relievers, stomach and intestinal diseases, tumors, biosimilars, and others.

Regarding the role of Sandoz Egypt in the social responsibility sector, the company contributed during the past year to reducing the negative effects of the Corona pandemic through the participation of the “Egyptian Food Bank” to be part of its initiatives to support the Egyptian families most in need with basic aid and the provision of food boxes.

El Bagoury stressed that Sandoz Egypt has not abandoned its role in the field of social responsibility, through cooperation with the governmental and private sectors to support the local community, by providing patient support programs to provide medicines and raise awareness.

During the past year, Sandoz Egypt, and within the framework of a sense of responsibility towards patients and society, contributed to launching the “Star” educational program, to reach 600 pharmacists, during the period from December 2019 to March 2020, and the program is accredited by the University of Wisconsin in the United States.

She also participated in the conference “The Egyptian Experience in Combating the Corona Virus” organized by the Egyptian government with the support of the Scientific Committee of the Ministry of Health to combat the emerging corona virus, and in cooperation with the Egyptian Society of Thoracic Diseases and Tuberculosis.

Al-Bagoury indicated that the company, in cooperation with Novartis Pharma for Pharmaceuticals, contributed to providing preventive personal tools for the emerging corona virus, for the benefit of the Ministry of Health.

El-Bagoury explained that the last period witnessed a remarkable development in the Egyptian drug market, which resulted in the formation of new bodies to regulate work in the market, such as the Egyptian Authority for Unified Purchase and Medical Supply, or the Egyptian Medicines Authority, as well as the application of the comprehensive health insurance system, which will contribute to raising the efficiency of the medical system in Egypt.

He added that adapting and preparing to deal with these positive changes in the health system is the most important challenge facing pharmaceutical companies during the coming period.

He pointed out that the establishment of the drug city is an important step, as medicine is a product of strategic importance, and the demand for medicine will continue to increase, and the role of the drug city comes in meeting the pharmaceutical needs not in the local market, but in the Middle East and Africa.

He pointed out that the presence of the drug city will greatly support the market. There are many partnerships with global entities in manufacturing, which will greatly contribute to the provision of modern medicines at competitive prices, and contribute to raising the health efficiency of citizens in a very large way.

El Bagoury emphasized that the Egyptian market is one of the promising markets. Some of the decisions taken during the last period had a clear impact on enhancing competitiveness in the Egyptian market, such as approving the law regulating medical and clinical research known as clinical and pre-clinical trials.

He added that these decisions will encourage many international companies to invest in Egypt, not only in manufacturing and consumption, but also in important research areas.

Also, pharmaceutical policies in Egypt have developed in an unprecedented way in drug registration strategies with a new thought, since the Egyptian Medicines Authority assumed responsibility in line with what is being aspired to from the renaissance of the health system, in line with the directions of the political leadership in Egypt’s future vision 2030.

Al-Bagoury explained that the registration procedures in general witnessed an improvement in the speed of obtaining marketing licenses and expedited and emergency registration to keep pace with the shortage of some preparations, and the availability of high-quality examples at an appropriate price, especially in the protocols for treating the Corona pandemic.

He pointed out that the Ministry of Health made a great effort in registering and making the Corona virus vaccine available in record time, in addition to the digital transformation in submitting all registration files to the Egyptian Medicines Authority in its various central departments, which was reflected in the accuracy and speed of completing the procedures.

He pointed out that the regulatory procedures for the registration of biological products have become up to the level of global health authorities. The normal registration process for new medicines used to take on average about 3 or 4 years, but when it comes to strategically important products such as biosimilars and products that are not available due to shortages; The Ministry of Health was supportive of completing all the registration process in just 6 months.

The article “Sandoz Egypt” plans to launch new drugs targeting 12 million patients was written in Al Borsa newspaper.